Literature DB >> 22988873

Phosphorylation of LRRK2: from kinase to substrate.

Evy Lobbestael1, Veerle Baekelandt, Jean-Marc Taymans.   

Abstract

The PD (Parkinson's disease) protein LRRK2 (leucine-rich repeat kinase 2) occurs in cells as a highly phosphorylated protein, with the majority of phosphosites clustering in the region between the ankyrin repeat and leucine-rich repeat domains. The observation that several pathogenic variants of LRRK2 display strongly reduced cellular phosphorylation suggests that phosphorylation of LRRK2 is involved in the PD pathological process. Furthermore, treatment of cells with inhibitors of LRRK2 kinase activity, which are currently considered as potential disease-modifying therapeutics for PD, leads to a rapid decrease in the phosphorylation levels of LRRK2. For these reasons, understanding the cellular role and regulation of LRRK2 as a kinase and as a substrate has become the focus of intense investigation. In the present review, we discuss what is currently known about the cellular phosphorylation of LRRK2 and how this relates to its function and dysfunction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988873     DOI: 10.1042/BST20120128

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  19 in total

1.  Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Authors:  Xiaodong Ding; Sandeep K Barodia; Lisha Ma; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

2.  Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.

Authors:  Kathrin Muda; Daniela Bertinetti; Frank Gesellchen; Jennifer Sarah Hermann; Felix von Zweydorf; Arie Geerlof; Anette Jacob; Marius Ueffing; Christian Johannes Gloeckner; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

3.  Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis.

Authors:  Chi G Weindel; Eduardo L Martinez; Xiao Zhao; Cory J Mabry; Samantha L Bell; Krystal J Vail; Aja K Coleman; Jordyn J VanPortfliet; Baoyu Zhao; Allison R Wagner; Sikandar Azam; Haley M Scott; Pingwei Li; A Phillip West; Jason Karpac; Kristin L Patrick; Robert O Watson
Journal:  Cell       Date:  2022-07-30       Impact factor: 66.850

4.  Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.

Authors:  Evy Lobbestael; Jing Zhao; Iakov N Rudenko; Aleksandra Beylina; Fangye Gao; Justin Wetter; Monique Beullens; Mathieu Bollen; Mark R Cookson; Veerle Baekelandt; R Jeremy Nichols; Jean-Marc Taymans
Journal:  Biochem J       Date:  2013-11-15       Impact factor: 3.857

5.  Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate.

Authors:  Jean-Marc Taymans; Fangye Gao; Veerle Baekelandt
Journal:  J Vis Exp       Date:  2013-09-18       Impact factor: 1.355

Review 6.  The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Authors:  Fumitaka Kawakami; Takafumi Ichikawa
Journal:  Parkinsons Dis       Date:  2015-04-21

Review 7.  A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology.

Authors:  Pablo Porras; Margaret Duesbury; Antonio Fabregat; Marius Ueffing; Sandra Orchard; Christian Johannes Gloeckner; Henning Hermjakob
Journal:  Proteomics       Date:  2015-03-21       Impact factor: 3.984

Review 8.  Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation.

Authors:  Bernd K Gilsbach; Arjan Kortholt
Journal:  Front Mol Neurosci       Date:  2014-05-05       Impact factor: 5.639

9.  Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.

Authors:  Dong Hwan Ho; Hyejung Kim; Jisun Kim; Hyuna Sim; Hyunjun Ahn; Janghwan Kim; Hyemyung Seo; Kwang Chul Chung; Bum-Joon Park; Ilhong Son; Wongi Seol
Journal:  Mol Brain       Date:  2015-09-18       Impact factor: 4.041

10.  In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.

Authors:  Renée Vancraenenbroeck; Joren De Raeymaecker; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Arnout Voet; Veerle Baekelandt; Jean-Marc Taymans
Journal:  Front Mol Neurosci       Date:  2014-06-03       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.